Report Details
Contracted drug production - discover trends and segments with highest revenue potential

Where's outsourced pharma manufacturing heading? Visiongain's updated report predicts that industry's revenues from 2013. There you find potentials for sales growth, also understanding trends, technologies for drugs, clients' needs, and opportunities.

That study gives you revenue forecasts to 2023 at overall world market, submarket, and national level. Avoid falling behind, then. Instead see what's happening for those medical contracting services - outsourcing and off-shoring - finding how you can gain.

Read on to scan that industry and see what its future market could be worth.

Forecasts from 2013-2023 and other analyses show you the commercial prospects

Besides revenue forecasting to 2023, our new study shows you historical data, growth rates, and market shares. Hear, too, about developments in technology and service offerings. You also get 82 tables, 61 charts, and three interviews with leaders in companies.

Gains through understanding those outsourcing services - advantages for your work

Data searches can be hard work - all that looking. But now you can stay ahead in knowledge for contracted drug making, benefiting your research, analysis, and decisions. Finding information you need for producing medicines just got quicker and easier.

Use our predictions to help expand your business and give you more influence. You get the forecasting leaders need. So avoid falling behind, instead trying our new report now.

There you hear what's happening in the industry for contract manufacturing organisations (CMOs). You also see where needs and money exist, to 2023, finding the potential gains.

The following sections show how you benefit from that new investigation.

Forecasts from 2013 for the world market and submarkets for outsourced drug producing

What are the secrets of that industry's progress? Discover expected trends there. Along with prediction of the overall world market for out-contracting drug production, our report shows you revenue forecasting of 11 submarkets to 2023 at world level:
• Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs), and related products
• Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages, and other agents
• Other applications of outsourced production - other services
• Clinical manufacturing
• Commercial manufacturing.

Those analyses and discussions show you commercial potentials for manufacturing service providers and their technologies. Discover those money-gaining prospects.

You find geographical revenue predictions too.

National and regional markets - what outlooks for demand, service provision, and sales?

In developed and developing countries, opportunities for pharmaceutical CMOs will occur, often with rising potential. You see where and how.

Our analyses give individual revenue forecasts to 2023 for 12 national markets:
• United States (US)
• Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5), with an EU forecast
• BRIC countries - Brazil, Russia, India, and China
• South Korea.

There you hear about progress and outlooks. You find opportunity. Assess that medical production sector's future - hear about developments and find their significance.

See there what's likely to happen. Our work explains, exploring issues.

Developments, challenges, and opportunities affecting CMOs and clients

The report shows you activities and events affecting that industry and market from 2013, including these:
• Trends for investing in biopharma manufacturing
• Demands for formulation developing services
• Potential for microreactors in drug making
• EU regulations and API production
• Backwards integration for generics manufacturers
• US generic drug user fee act and API producing.

Our analysis discusses other aspects of the technologies and services too, including these:
• Investment in HPAPI manufacturing facilities
• Demand for softgel formulations and the shift to continuous manufacturing
• Complex-molecule production, esp. biologics (inc. biosimilars) and orphan drugs
• Development of antibody-drug conjugates (ADCs)
• Lyophilisation, other drying technology, and aseptic filling
• Technologies to stimulate market expansion.

There you explore political, economic, social, and technological questions, assessing outlooks for business. Examine what forces stimulate and what restrain that industry.

You also see regulatory developments. You discover, then, what that industry's present and future hold, exploring issues for clients and service providers.

Companies and overall 2017 market value - how high can revenues go?

What's possible for that industry? Our analysis predicts the world market for contract pharma manufacturing will reach $69.7bn in 2017. It will rise from $51.7bn in 2012, with growth to 2023.

Our study explains what service needs, pharma technologies, and outsourcing providers hold greatest commercial potential.

In particular, you explore activities of these companies:
• Catalent Pharma Solutions
• Lonza
• Evonik Degussa
• Royal DSM
• Teva API.

You also find discussions of these firms, among other players:
• Patheon
• Boehringer BioXcellence
• Famar
• Fareva
• Vetter Pharma.

There you analyse participants' financial results, market shares, activities, and outlooks. You find 150 organisations mentioned. You also read three interviews with companies.

Discover what authorities there do, say, and think, helping you stay ahead.

Research and analysis on the CMO industry and market - data found nowhere else

In particular, then, our new investigation gives you these advantages:
• Revenues to 2023 for outsourced medicine production at world level, with forecasting of 11 submarkets - explore prospects for sales and investments
• Forecasts to 2023 for 12 national markets in the Americas, Europe, and Asia - investigate developed and developing countries for revenue potentials
• Outlooks for established and rising CMOs - assess market shares, portfolios, results, capabilities, clients, and prospects.

Pharma Contract Manufacturing: World Market Outlook 2013-2023 provides independent analysis. There you receive business intelligence found only in our work, finding where money lies.

Gain recognition, too, for insight. With that report you're less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analysis, and decisions, also saving time.

Table Of Contents

1. Executive Summary

1.1 Pharma Contract Manufacturing: World Market Overview 2013
1.2 Report Contents
1.3 Research and Analysis Methods
1.4 An Introduction to Pharma Contract Manufacturing
1.4.1 Why Outsource in the Pharma Industry?
1.4.2 Services Offered by CMOs
1.4.3 Tactical and Strategic Manufacturing Outsourcing
1.4.4 Trends in Contract Manufacturing 2013-2023

2. The Pharma Contract Manufacturing Market: Outlook and Forecast 2013-2023

2.1 The Pharma Contract Manufacturing: Market Performance 2010-2012
2.1.1 Contract Manufacturing Is the Most Mature Pharma Outsourcing Sector
2.1.2 The Pharma Contract Manufacturing Market by Sector 2012
2.2 Pharma Contract Manufacturing: Overall Market Forecast 2013-2023
2.2.1 What Will Drive Growth for Contract Manufacturers 2013-2023?
2.2.2 Will Generics Drive or Restrain Market Growth in this Decade?
2.2.3 Outlook and Revenue Forecast for Other Contract Manufacturing Services 2013-2023
2.2.3.1 Rising Demand for Formulation Development Services
2.3 Clinical and Commercial Manufacturing Services
2.3.1 Clinical-Stage Manufacturing: Submarket Forecast 2013-2023
2.3.2 Commercial-Stage Manufacturing: Submarket Forecast 2013-2023
2.4 Leading Contract Manufacturing Organisations (CMOs) 2013
2.4.1 Catalent Pharma Solutions: The Market Leader
2.4.1.1 Expanding in Clinical and Biopharma Manufacturing
2.4.2 Lonza: An Expert in Biopharma Manufacturing
2.4.2.1 Lonza and Advanced Biopharma Manufacturing
2.4.3 Evonik Degussa: A Small Molecule Specialist
2.4.3.1 Growth in HPAPI Manufacturing
2.4.4 Royal DSM
2.4.4.1 Adding Biopharma Capacity
2.4.5 Teva API: The World's Largest API Manufacturer
2.4.5.1 Will Teva Expand in Emerging Markets?
2.4.6 Patheon
2.4.6.1 Patheon Is Adding New Formulation Development Services
2.4.7 Boehringer BioXcellence: Boehringer's Biopharma Manufacturing Division
2.4.7.1 Adding New Services for Growth
2.4.8 Famar
2.4.9 Fareva
2.4.10 Vetter Pharma: Aseptic Filling for Biologics and Small Molecules
2.4.10.1 Vetter Offers its Clients New Services

3. The Contract API Manufacturing Submarket: Outlook 2013-2023

3.1 The Contract API Manufacturing Submarket 2012
3.1.1 The API Manufacturing Submarket by Sector 2012
3.2 The Contract API Manufacturing Submarket Outlook 2013-2023
3.2.1 The Contract API Manufacturing Submarket Forecast 2013-2023
3.2.2 What Will Drive Submarket Growth to 2023?
3.2.2.1 The Potential for Microreactors in Commercial Manufacturing to 2023
3.2.3 How Will New EU Regulations Impact the API Manufacturing Submarket?
3.2.4 Contract API Manufacturing Submarket Restraints 2013-2023
3.2.4.1 Backwards Integration for Generics Manufacturers
3.3 The Contract Generic API Manufacturing Submarket 2013-2023
3.3.1 The Contract Generic API Manufacturing Submarket Forecast 2013-2023
3.3.2 The Contract Generic API Manufacturing Submarket Drivers and Restraints to 2023
3.3.2.1 The US Generic Drug User Fee Act and API Manufacturing
3.4 The Contract HPAPI Manufacturing Submarket 2013-2023
3.4.1 Challenges and Opportunities in High Containment Manufacturing
3.4.2 Many Companies Are Investing in HPAPI Manufacturing Facilities
3.4.3 The Contract HPAPI Manufacturing Submarket Forecast 2013-2023
3.4.4 Submarket Drivers and Restraints 2013-2023

4. The Contract FDF Manufacturing Submarket Outlook 2013-2023

4.1 The Contract FDF Manufacturing Submarket 2012
4.1.1 Solid Dosage Manufacturing Leads the Market
4.1.2 CMOs Report High Demand for Softgel Formulations
4.2 The Contract FDF Manufacturing Submarket Forecast 2013-2023
4.2.1 Complex Molecule Manufacturing Will Drive Growth to 2023
4.2.2 What Will Restrain Growth in FDF Outsourcing in this Decade?
4.3 The Contract Solid Dosage Manufacturing Submarket 2013-2023
4.3.1 How Will Revenues for Solid Dosage Manufacturing Grow 2013-2023?
4.3.2 Submarket Drivers and Restraints 2013-2023
4.3.2.1 Will Product Reformulation Drive Growth to 2023?
4.4 The Contract Injectable Dosage Manufacturing Submarket 2013-2023
4.4.1 The Contract Injectable Dosage Manufacturing Submarket Forecast 2013-2023
4.4.1.1 Drug Shortages Offer an Opportunity for CMOs in the Short Term
4.4.2 Demand for Biopharma Manufacturing Will Drive Growth 2013-2023
4.4.2.1 Interest in Antibody Drug Conjugate Development Is Growing
4.4.3 Lyophilisation and Aseptic Filling Demand Will Rise
4.4.3.1 Will Spray Drying Replace Lyophilisation in FDF Manufacturing?

5. Pharma Contract Manufacturing: Leading Developed National Markets 2013-2023

5.1 Leading National Markets for Pharma Contract Manufacturing 2012
5.1.1 Challenges in Assessing the Market: Supply vs. Demand
5.1.2 Leading National Pharma Contract Manufacturing Markets: Revenue Forecasts 2013-2023
5.2 The US Is the Leading National Market in Terms of Demand
5.2.1 Pharma Manufacturing in the US: Regulatory Oversight 2013
5.2.1.1 Controlling Foreign Manufacturing Sites
5.2.1.2 What Impact Will the GDUFA 2012 Have on Foreign Manufacturing?
5.2.1.3 Outsourcing and US Manufacturing Regulations
5.2.2 Increased Demand for Domestic API Manufacturing?
5.2.3 The US Contract Manufacturing Submarket Forecast 2013-2023
5.3 Outlook for Pharma Contract Manufacturing in the EU
5.3.1 The EU is the leading Destination for Pharma Contract Manufacturing
5.3.2 Regulatory Aspects to Pharma Manufacturing in the EU
5.3.2.1 The European Commission Amends Annex 16
5.3.2.2 The Falsified Medicine Directive: Controlling Foreign API Imports
5.3.3 Biopharma Manufacturing Demand Will Rise to 2023
5.3.4 The EU Contract Manufacturing Submarket Forecast 2013-2023
5.3.5 Germany: The Leading EU Destination for API and FDF Manufacturing
5.3.5.1 Demand for Contract Manufacturing in Germany: Revenue Forecast 2013-2023
5.3.6 CMOs Account for a Third of Manufacturing Sites in France
5.3.6.1 French Pharma Contract Manufacturing Submarket Forecast 2013-2023
5.3.7 Italy: Strong API Manufacturing Traditions
5.3.7.1 Revenue Forecast for the Italian Pharma Contract Manufacturing Submarket 2013-2023
5.3.8 Spain: How Will Demand for Manufacturing Services Grow to 2023?
5.3.9 The UK: Pharma Contract Manufacturing Submarket Forecast 2013-2023
5.4 Pharma Contract Manufacturing in Japan 2013-2023
5.4.1 Pharma Manufacturing Regulations in Japan
5.4.1.1 The Pharmaceutical Affairs Law
5.4.2 Greater API Outsourcing to Drive Japanese Submarket Growth to 2023

6. Pharma Contract Manufacturing: Leading Emerging National Markets 2013-2023

6.1 Pharma Contract Manufacturing in Emerging Markets
6.1.1 Outsourcing to Emerging Markets from Developed Markets
6.1.1.1 Demand for Services in India and China
6.1.2 Domestic Demand for Pharma Contract Manufacturing Services
6.1.3 Pharma Contract Manufacturing: Leading Emerging National Market Forecasts 2013-2023
6.2 Chinese Demand for Pharma Contract Manufacturing Services 2013-2023
6.2.1 Improved Manufacturing Regulations in China
6.2.1.1 New Regulations for Excipients and Guidance for API Manufacturing 2012-2013
6.2.1.2 What Are the Consequences to Stricter Manufacturing Regulations in China?
6.2.2 Chinese CMOs Are Investing in Biopharma Manufacturing
6.2.3 China Pharma Contract Manufacturing Submarket Forecast 2013-2023
6.3 India: CMOs with Growing Formulation Experience
6.3.1 Regulatory Outlook for Indian Pharma Manufacturing
6.3.1.1 Ensuring Compliance with New Rules in the EU
6.3.2 Domestic Manufacturing Dominates the Indian Pharma Market
6.3.3 Demand for Contract Manufacturing in India: Submarket Forecast 2013-2023
6.4 Brazil: Contract Manufacturing Outlook 2013-2023
6.4.1 Pharma Manufacturing Regulations in Brazil
6.4.1.1 New Guidelines and Regulations Proposed 2012-2013
6.4.2 Brazil Imports Most of its APIs
6.4.3 Brazil: Pharma Contract Manufacturing Submarket Forecast 2013-2023
6.5 The Russian Pharma Contract Manufacturing Submarket 2013-2023
6.5.1 Pharma Manufacturing Regulations in Russia 2013
6.5.1.1 Compliance with GMP in Russia
6.5.2 How Will Demand for Contract Manufacturing Grow in Russia 2013-2023?
6.6 South Korea
6.6.1 South Korea: Strict GMP Regulations
6.6.2 South Korea: Pharma Contract Manufacturing Submarket Forecast 2013-2023

7. Pharma Contract Manufacturing Industry Trends: CMO Perspective 2013-2023

7.1 Pharma Contract Manufacturing Market: Strengths and Weaknesses for CMOs 2012-2013
7.2 Pharma Contract Manufacturing Market: Opportunities and Threats for CMOs 2013-2023
7.3 Pharma Contract Manufacturing Market: STEP Analysis 2013-2023
7.3.1 Social Factors
7.3.2 New Technologies Will Drive Market Growth to 2023
7.3.2.1 Single-Use Technologies in Biopharma Manufacturing
7.3.2.2 Green Technology in Contract Manufacturing
7.3.2.3 Drug Delivery Trends and CMOs
7.3.2.4 Biologics Are Causing Increased Demand for Lyophilisation
7.3.2.5 Improving Solubility and Stability for Small Molecules
7.3.2.6 Spray Drying as an Alternative to Lyophilisation
7.3.2.7 Hot-Melt Extrusion
7.3.3 Economic Pressures
7.3.3.1 Developed-Market CMOs Face Competition from Emerging Markets
7.3.4 Political Issues
7.3.4.1 How Will Regulatory Developments Affect CMOs?
7.4 Trends in Drug Development that Will Impact CMOs to 2023
7.4.1 Orphan Drug Development: Smaller Manufacturing Capacities
7.4.2 Complex Biologics: Interest in ADCs Is Rising
7.4.3 How Will Biosimilar Market Growth Affect CMOs?
7.4.4 The Future of Small Molecule Outsourcing
7.5 How Will CMOs Expand in the Coming Decade?
7.5.1 CMO Consolidation Will Increase
7.5.2 There Will be More Manufacturing Facilities Available for Acquisition
7.6 Developments in the Manufacturing Process 2013-2023
7.6.1 Quality by Design (QbD)
7.6.2 A Move Towards Continuous Manufacturing?

8. Pharma Contract Manufacturing Industry Trends: Client Perspective 2013-2023

8.1 Pharma Contract Manufacturing: Client Perspective Industry Strengths and Weaknesses 2012-2013
8.2 Pharma Contract Manufacturing: Client Perspective Industry Opportunities and Threats 2013-2023
8.3 Important Aspects of the Outsourcing Decision
8.3.1 What Factors Will Influence CMO Selection?
8.3.2 CMO-Pharma Partnering Models
8.3.3 Strategic Partnering
8.3.4 Selecting a Local CMO vs. Offshoring
8.3.5 CMOs in Emerging Markets
8.3.6 Communication
8.3.7 Ensuring Protection in Intellectual Property and Tech Transfer
8.3.8 Regulatory Compliance is a Key Deciding Factor for Pharma Clients
8.3.8.1 Regulatory Bodies and Outsourcing
8.3.8.2 Global Harmonisation Will Improve Compliance
8.4 Trends in Outsourcing Partnerships 2013-2023
8.4.1 Big Pharma and Outsourced Manufacturing
8.4.2 Small and Virtual Pharma Companies
8.4.3 How Will Biotech Funding Impact the Pharma Contract Manufacturing Industry to 2023?

9. Research Interviews 2013

9.1 Interview with Heiner Hoppmann, CEO, Aenova
9.1.1 Aenova
9.1.1.1 Aenova Grows Organically and through Acquisitions
9.1.2 Changes in Customer Demand to 2023
9.1.2.1 CMO Globalisation
9.1.3 Trends in Drug Development Will Alter Customer Demands
9.1.4 How Will Advances in Technology Benefit CMOs?
9.1.4.1 Limited Expectations for Hot-Melt Extrusion
9.1.5 Increased Demand for Effervescents?
9.1.6 Growth through Consolidation
9.1.7 Batch vs. Continuous Manufacturing
9.2 Interview with Dr Abhinav Shukla, Vice President, Process Development and Manufacturing, KBI Biopharma
9.2.1 KBI Biopharma
9.2.2 Single-Use Technologies in Biopharma Manufacturing
9.2.3 Demands for Biopharma Manufacturing Services
9.2.4 Outlook for the US Contract Manufacturing Market
9.3 Interview with Shawn Cavanagh, COO, Cambrex
9.3.1 Cambrex
9.3.2 Demand for API Manufacturing Services
9.3.3 Commercial Restraints in the API Manufacturing Market
9.3.4 The Opportunity in HPAPI Manufacturing
9.3.5 Technological Developments in API Manufacturing to 2023

10. Conclusions to the Study

10.1 The World Pharma Contract Manufacturing Market 2012
10.2 Outlook for the Market to 2023
10.2.1 Rising Demand for High Value Services 2013-2023
10.2.2 Demand Will be Highest Among Developed Market Clients
10.3 Which New Technologies Will Stimulate Demand to 2023?

List of Tables

Table 1.1 Currency Exchange Rates
Table 2.1 Pharma Contract Manufacturing Market Revenue ($bn), 2011-2012
Table 2.2 Pharma Outsourcing Market CAGRs (%) by Sector, 2012-2017 and 2017-2023
Table 2.3 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Sector, 2012
Table 2.4 Pharma Contract Manufacturing Market: Overall Market and Revenue Forecasts by Sector ($bn), 2012-2023
Table 2.5 Pharma Contract Manufacturing Market: Submarket Shares (%), 2012-2023
Table 2.6 Other Services Submarket Forecast ($bn), 2012-2023
Table 2.7 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Development Stage, 2012
Table 2.8 Clinical Manufacturing Submarket Forecast ($bn), 2012-2023
Table 2.9 Commercial Manufacturing Submarket Forecast ($bn), 2012-2023
Table 2.10 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Company, 2012
Table 2.11 Catalent: Revenue ($bn), 2008-2012
Table 2.12 Lonza Custom Manufacturing: Revenue ($bn), 2008-2012
Table 2.13 DSM Pharmaceutical Products: Revenue ($bn), 2008-2012
Table 2.14 Teva API: Revenue, 2008-2012
Table 2.15 Patheon: Revenue ($bn), 2008-2012
Table 2.16 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2011-2012
Table 2.17 Famar: Revenue ($bn), 2007-2011
Table 3.1 Contract API Manufacturing Submarket Revenue ($bn), 2011-2012
Table 3.2 Contract API Manufacturing Submarket: Revenue ($bn) and Submarket Share (%) by Sector, 2012
Table 3.3 Contract API Manufacturing Submarket: Overall Submarket and Revenue Forecasts by Sector ($bn), 2012-2023
Table 3.4 Contract API Manufacturing Submarket: Submarket Shares (%), 2012-2023
Table 3.5 Contract API Manufacturing Submarket: Drivers and Restraints, 2013-2023
Table 3.6 Contract Generic API Manufacturing Submarket Forecast ($bn), 2012-2023
Table 3.7 Contract Generic API Manufacturing Submarket: Drivers and Restraints, 2013-2023
Table 3.8 Contract HPAPI Manufacturing Submarket Forecast ($bn), 2012-2023
Table 3.9 Contract HPAPI Manufacturing Submarket: Drivers and Restraints, 2013-2023
Table 4.1 Contract FDF Manufacturing Submarket Revenue ($bn), 2011-2012
Table 4.2 Contract FDF Manufacturing Submarket: Revenue ($bn) and Submarket Share (%) by Sector, 2012
Table 4.3 Contract FDF Manufacturing Submarket: Overall Submarket and Revenue Forecasts by Sector ($bn), 2012-2023
Table 4.4 Contract FDF Manufacturing Submarket: Submarket Shares (%), 2012-2023
Table 4.5 Contract FDF Manufacturing Submarket: Drivers and Restraints, 2013-2023
Table 4.6 Contract Solid Dosage Manufacturing Submarket Forecast ($bn), 2012-2023
Table 4.7 Contract Solid Dosage Manufacturing Submarket: Drivers and Restraints, 2013-2023
Table 4.8 Contract Injectable Dosage Manufacturing Submarket Forecast ($bn), 2012-2023
Table 4.9 Contract Injectable Dosage Manufacturing Submarket: Drivers and Restraints, 2013-2023
Table 4.10 ADCs in Phase II and III Development, 2013
Table 4.11 Selected CMOs Investing in ADC Manufacturing Capacity, 2011-2013
Table 5.1 Pharma Contract Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2012
Table 5.2 Pharma Contract Manufacturing Market: Regional Revenue Forecasts ($bn), 2013-2023
Table 5.3 Pharma Contract Manufacturing Market: Developed Countries' Submarket Shares (%), 2012-2023
Table 5.4 GDUFA: Annual Fees for Domestic and Foreign Manufacturing Sites, 2013-2017
Table 5.5 US Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Table 5.6 EU Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Country, 2012
Table 5.7 Catalent: Revenue ($bn) and Assets (%) by Region, 2012
Table 5.8 Cambrex: Revenue ($bn) by Region, 2012
Table 5.9 EU Pharma Contract Manufacturing Market: National Submarket Forecasts ($bn), 2012-2023
Table 5.10 German Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Table 5.11 Selected French Manufacturing Site Acquisitions, 2009-2013
Table 5.12 French Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Table 5.13 Italian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Table 5.14 Spanish Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Table 5.15 UK Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Table 5.16 Japanese Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Table 6.1 Pharma Contract Manufacturing Market: Emerging Market Revenue ($bn) and Market Share (%) by Country, 2012
Table 6.2 Pharma Contract Manufacturing Market: Emerging Market Submarket Forecasts ($bn), 2012-2023
Table 6.3 Pharma Contract Manufacturing Market: Emerging Market Submarket Shares (%), 2012-2023
Table 6.4 Chinese Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Table 6.5 FDA DMF Filings from Indian Pharma Manufacturers, 2012
Table 6.6 Indian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Table 6.7 Brazilian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Table 6.8 Russian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Table 6.9 South Korean Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Table 7.1 Pharma Contract Manufacturing Market Strengths and Weaknesses: CMO Perspective, 2013-2023
Table 7.2 Pharma Contract Manufacturing Market Opportunities and Threats: CMO Perspective, 2013-2023
Table 7.3 Pharma Contract Manufacturing Market: STEP Analysis, 2013-2023
Table 7.4 Pre-Filled Syringe Filling Market: Revenue ($bn) and Market Share (%) by Company, 2012
Table 7.5 Selected Lyophilisation Service Providers, 2013
Table 7.6 Lyophilisation vs. Spray Drying: A Comparison
Table 7.7 Selected Orphan Drug Prices, 2013
Table 7.8 Biological Manufacturing Expansion, 2011-2013
Table 7.9 Selected CMOs Growing Faster than the Market, 2007-2012
Table 7.10 Regional Market Expansion, 2010-2012
Table 8.1 Pharma Contract Manufacturing Market Strengths and Weaknesses: Client Perspective, 2013-2023
Table 8.2 Pharma Contract Manufacturing Market Opportunities and Threats: Client Perspective, 2013-2023
Table 8.3 Benefits and Risks to Outsourcing Pharma Manufacturing, 2013
Table 8.4 World Population by Country, 2013
Table 8.5 ICH Guidelines: Key Facts and Adoption, 2000-2012
Table 9.1 Aenova: Revenue ($bn), 2011-2013
Table 9.2 Cambrex: Revenue ($bn), 2008-2012
Table 10.1 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Sector, 2012, 2017 and 2023
Table 10.2 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Region, 2012, 2017 and 2023

List of Figures

Figure 1.1 Selected Services Offered by CMOs, 2013
Figure 1.2 Major Trends Affecting Pharma Contract Manufacturing Revenue Growth, 2013-2023
Figure 2.1 Pharma Contract Manufacturing Market Revenue ($bn), 2011-2012
Figure 2.2 Pharma Contract Manufacturing: Market Share (%) by Sector, 2012
Figure 2.3 Pharma Contract Manufacturing Market Forecast ($bn), 2012-2023
Figure 2.4 Pharma Contract Manufacturing Market: Submarket Shares (%), 2017
Figure 2.5 Pharma Contract Manufacturing Market: Submarket Shares (%), 2023
Figure 2.6 Pharma Contract Manufacturing Market: Drivers, 2013-2023
Figure 2.7 Pharma Contract Manufacturing Market: Restraints, 2013-2023
Figure 2.8 Other Services Submarket Forecast ($bn), 2012-2023
Figure 2.9 Pharma Contract Manufacturing: Market Share (%) by Developmental Stage, 2012
Figure 2.10 Clinical Manufacturing Submarket Forecast ($bn), 2012-2023
Figure 2.11 Commercial Manufacturing Submarket Forecast ($bn), 2012-2023
Figure 2.12 Pharma Contract Manufacturing Market: Market Share (%) by Company, 2012
Figure 2.13 Catalent: Revenue ($bn), 2008-2012
Figure 2.14 Lonza Custom Manufacturing: Revenue ($bn), 2008-2012
Figure 2.15 DSM Pharmaceutical Products: Revenue ($bn), 2008-2012
Figure 2.16 Teva API: Revenue ($bn), 2008-2012
Figure 2.17 Patheon: Revenue ($bn), 2008-2012
Figure 2.18 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2011-2012
Figure 2.19 Famar: Revenue ($bn), 2007-2011
Figure 3.1 Contract API Manufacturing Submarket Revenue ($bn), 2011-2012
Figure 3.2 Contract API Manufacturing Submarket: Submarket Share (%) by Sector, 2012
Figure 3.3 Contract API Manufacturing Submarket Forecast ($bn), 2012-2023
Figure 3.4 Contract API Manufacturing Submarket: Submarket Shares (%), 2017
Figure 3.5 Contract API Manufacturing Submarket: Submarket Shares (%), 2023
Figure 3.6 Contract Generic API Manufacturing Submarket Forecast ($bn), 2012-2023
Figure 3.7 Contract HPAPI Manufacturing Submarket Forecast ($bn), 2012-2023
Figure 4.1 Contract FDF Manufacturing Submarket Revenue ($bn), 2011-2012
Figure 4.2 Contract FDF Manufacturing Submarket: Submarket Share (%) by Sector, 2012
Figure 4.3 Contract FDF Manufacturing Submarket Forecast ($bn), 2012-2023
Figure 4.4 Contract FDF Manufacturing Submarket: Submarket Shares (%), 2017
Figure 4.5 Contract FDF Manufacturing Submarket: Submarket Shares (%), 2023
Figure 4.6 Contract Solid Dosage Manufacturing Submarket Forecast ($bn), 2012-2023
Figure 4.7 Contract Injectable Dosage Manufacturing Submarket Forecast ($bn), 2012-2023
Figure 5.1 Pharma Contract Manufacturing Market: Developed Market Share (%) by Region, 2012
Figure 5.2 Pharma Contract Manufacturing Market: Developed Market Share (%) by Region, 2017
Figure 5.3 Pharma Contract Manufacturing Market: Developed Market Share (%) by Region, 2023
Figure 5.4 US Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Figure 5.5 EU Pharma Contract Manufacturing Market: Market Share (%) by Country, 2012
Figure 5.6 EU Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Figure 5.7 German Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Figure 5.8 French Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Figure 5.9 Italian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Figure 5.10 Spanish Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Figure 5.11 UK Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Figure 5.12 Japanese Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Figure 6.1 Pharma Contract Manufacturing Market: Emerging Market Share (%) by Country, 2012
Figure 6.2 Pharma Contract Manufacturing Market: Emerging Market Share (%) by Country, 2012, 2017 and 2023
Figure 6.3 Chinese Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Figure 6.4 Indian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Figure 6.5 Brazilian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Figure 6.6 Russian Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Figure 6.7 South Korean Pharma Contract Manufacturing: Submarket Forecast ($bn), 2012-2023
Figure 7.1 Pre-Filled Syringe Filling Market: Market Share (%) by Company, 2012
Figure 7.2 Biosimilar Market Forecast ($bn), 2012, 2017 and 2023
Figure 8.1 Overview of ICH Manufacturing Guidelines, 2013
Figure 9.1 Aenova: Revenue ($bn), 2011-2013
Figure 9.2 Cambrex: Revenue ($bn), 2008-2012
Figure 10.1 Pharma Contract Manufacturing Market: Revenue ($bn) by Sector, 2012, 2017 and 2023
Figure 10.2 Pharma Contract Manufacturing Market: Revenue ($bn) by Region, 2012, 2017 and 2023

Companies Listed

ACS Green Chemistry Institute
Aegerion Pharmaceuticals
Aenova
Aesica Pharmaceuticals
Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
Alexion Pharmaceuticals
Almac Group
Althea Technologies
AMRI
API Corporation (APIC)
Aptuit
Arch Pharmalabs
Archimica (part of Euticals)
Asociación Española de Fabricantes de Productos de Química Fina (AFAQUIM) [Spain]
Aspen Pharmacare
Associação Brasileira da Indústria Farmoquímica e de Insumos Farmacêuticos (ABIQUIFI) [Brazil]
AstraZeneca
Aurobindo Pharma
Banner Pharmacaps (part of Patheon)
Bausch and Lomb (part of Valeant Pharmaceuticals)
Bayer
Ben Venue Laboratories (part of Boehringer Ingelheim)
Bend Research
Biogen Idec
Biotest
Blackstone Group
Boehringer Ingelheim
Boehringer Ingelheim BioXcellence (part of Boehringer Ingelheim)
Bristol-Myers Squibb
Cadila Healthcare
Cambrex
Cambridge Major Laboratories (CML)
Carbogen Amcis (part of Dishman Pharmaceuticals and Chemicals)
Catalent (Shanghai) Clinical Trial Supplies
Catalent Pharma Solutions
Cedarburg Hauser Pharmaceuticals
Celldex Therapeutics
Celltrion
Cenexi
Central Drugs Standard Control Organization (CDSCO) [India]
Chemtrix
China Food and Drug Administration (CFDA)
Cook Pharmica
Covance
CTC Bio
Daito Pharmaceutical
Delpharm
Department of Health and Family Welfare [India]
Department of Pharmaceuticals [India]
Dishman Pharmaceuticals and Chemicals
Dr. Reddy's Laboratories
DSM Sinochem Pharmaceuticals
Eli Lilly
Emcure Pharmaceuticals
Esteve Química
Euro Vital Pharma (part of Aenova)
European Commission
European Medicines Agency (EMA)
Euticals
Evonik Degussa (part of Evonik Industries)
Evonik Industries
Fabbrica Italiana Sintetici (FIS)
Famar
Fareva
FDA Office of Combination Products (OCP) [US]
Food and Drug Administration (FDA) [US]
Fujifilm Diosynth Biotechnologies
Granules India
Haupt Pharma
Hetero Drugs
Hexal Arzneimittel (part of Novartis)
Hospira
Hospira One2One
ImmunoGen
Immunomedics
Indian Pharmaceutical Alliance
Infa Group
Innovent Biologics
JK Pharmaceutical
KBI Biopharma
Korea Food and Drug Administration (KFDA)
kSep Systems
Lonza
Lupin Pharmaceuticals
Marinopoulos Group
Matrix Laboratories (part of Mylan)
McNeil Consumer Healthcare (part of JandJ)
Medice
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Merck and Co.
Ministry for Food and Drug Safety (MFDS) [South Korea]
Ministry of Health (MOH) [China]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Ministry of Industry and Information Technology (MIIT) [China]
Mitsui and Co.
Mylan
National Development and Reform Commission (NDRC) [China]
Neuland Laboratories
Nipro
Novartis
Novasep
NPS Pharmaceuticals
Nycomed (part of Takeda)
Office for National Statistics (ONS) [UK]
Orchid Chemicals and Pharmaceuticals
Patheon
Pfizer
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
Piramal Pharma Solutions
Quintiles
R5 Pharmaceuticals (part of Aesica Pharmaceuticals)
Recepta Biopharma
Recipharm
Redwood Bioscience
Rentschler Biotechnologie
Roche
ROVI Contract Manufacturing
Royal DSM
SAFC (part of Sigma-Aldrich)
SafeBridge Consultants
Saltigo
Samsung
Samsung BioLogics
Sandoz (part of Novartis)
Sanofi
SCM Pharma
Seattle Genetics
Shandong Xinhua Pharmaceutical Co
ShangPharma
Shire
Siegfried
Sigma-Aldrich
Sigmar Italia (part of Fareva)
Sinochem
SMS Pharmaceuticals (part of Mylan)
Stada Arzneimittel
Strides Arcolab
Temmler Group (part of Aenova)
Teva API (part of Teva)
Teva Pharmaceutical Industries
Thermo Fisher Scientific
UCB
UMN Pharma
UNIGEN (part of UMN Pharma)
University of Nottingham
Valeant Pharmaceuticals
Vetter Pharma
Vivante GMP Solutions (part of Lonza)
West Pharmaceutical Services
World Health Organization (WHO)
Wuxi AppTec
Zenara Pharmaceuticals
Zhangjiang Biotech and Pharmaceutical Base Development
Zhejiang Jiang Yuan Tang Biotechnology

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Shadi

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers

Connected Living

Connected Living

  • $ 15 000
  • Industry report
  • April 2014
  • by Frost & Sullivan

The research service sets the stage for visionary thinking by identifying and analyzing one of the significant Mega Trends—Connected Living—where ICT-enabled services are being offered to consumers ...

Commercial Vehicles 2020 Vision

Commercial Vehicles 2020 Vision

  • $ 15 000
  • Industry report
  • May 2014
  • by Frost & Sullivan

Green, Safe, and Connected Medium-heavy Trucks to Drive Future Freight Mobility Some of the key trends for OEMs globally are powertrains gaining strength in customer retention strategies, and vehicle platforms ...

Analysis of the Global Subsea Equipment Market

Analysis of the Global Subsea Equipment Market

  • $ 10 000
  • Industry report
  • June 2014
  • by Frost & Sullivan

With Advancements in Technology, Migration to Deep Waters is Increasing Steadily With new fields being discovered in the offshore regions, the declining recovery rate, and production from ageing fields, ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.